27 March 2025 in Translational Oncology
CCCamelia Alexandra Coadă
+11
Endometriosis (EMS) is a chronic, gynecological condition affecting 6-10 % of reproductive-age women. While these lesions are benign, ovarian EMS presents cancer-like features, and can progress to endometriosis-correlated ovarian cancer (ECOC) through a multistep process. Given the regulatory role of miRNAs in gene expression and biological pathways, we aimed to identify miRNAs associated with the malignant transformation of ovarian EMS, which could serve as a potential diagnostic tool for the early identification of such patients. Global miRNA profiling was performed in 8 patients with benign ovarian EMS (EMS-b) and 29 patients with ECOC. Differential expression analysis (DEA) of miRNAs between EMS-b, EMS tissues from patients with ECOC (EMS-k) and ECOC tissues was performed. Receiver Operating Characteristic (ROC) curves were built to evaluate the binary classification performance of significant miRNAs. Comparison between EMS-b and EMS-k revealed 13 significantly deregulated miRNAs. Furthermore, when comparing ECOC and EMS-b, we observed significant deregulation of 181 miRNAs. ROC analysis revealed a panel of seven upregulated miRNAs with accuracies above 0.7 in identifying EMS-k and EMS-b. Notably, four miRNAs (hsa-miR-200a-3p, hsa-miR-141-3p, hsa-miR-183-5p, hsa-miR-10a-5p) were consistently upregulated in both EMS-k and ECOC tissues, achieving accuracies above 0.77 in distinguishing between EMS-k and EMS-b. When used to distinguish between EMS-b and ECOC tissues, these miRNAs showed accuracies even higher, above 0.94. Specifically, hsa-miR-183-5p had an accuracy of 1, hsa-miR-200a-3p and hsa-miR-141-3p of 0.97, while hsa-miR-10a-5p of 0.95. Our study identified a panel of miRNA biomarkers that may serve as potential candidates for the early detection of ECOC in patients previously diagnosed with ovarian EMS.
21 June 2022 in Cancer Science
Preclinical forms of gastrointestinal stromal tumor (GIST), small asymptomatic lesions, called microGIST, are detected in approximately 30% of the general population. Gastrointestinal stromal tumor driver mutation can be already detected in microGISTs, even if they do not progress into malignant cancer; these mutations are necessary, but insufficient events to foster tumor progression. Here we profiled the tissue microbiota of 60 gastrointestinal specimens in three different patient cohorts—micro, low‐risk, and high‐risk or metastatic GIST—exploring the compositional structure, predicted function, and microbial networks, with the aim of providing a complete overview of microbial ecology in GIST and its preclinical form. Comparing microGISTs and GISTs, both weighted and unweighted UniFrac and Bray–Curtis dissimilarities showed significant community‐level separation between them and a pronounced difference in Proteobacteria, Firmicutes, and Bacteroidota was observed. Through the LEfSe tool, potential microbial biomarkers associated with a specific type of lesion were identified. In particular, GIST samples were significantly enriched in the phylum Proteobacteria compared to microGISTs. Several pathways involved in sugar metabolism were also highlighted in GISTs; this was expected as cancer usually displays high aerobic glycolysis in place of oxidative phosphorylation and rise of glucose flux to promote anabolic request. Our results highlight that specific differences do exist in the tissue microbiome community between GIST and benign lesions and that microbiome restructuration can drive the carcinogenesis process.
9 January 2024 in Cancer Science
Endometrial cancer (EC) is the most prevalent gynecological cancer in high‐income countries. Its incidence is skyrocketing due to the increase in risk factors such as obesity, which represents a true pandemic. This study aimed to evaluate microRNA (miRNA) expression in obesity‐related EC to identify potential associations between this specific cancer type and obesity. miRNA levels were analyzed in 84 EC patients stratified based on body mass index (BMI; ≥30 or <30) and nine noncancer women with obesity. The data were further tested in The Cancer Genome Atlas (TCGA) cohort, including 384 EC patients, 235 with BMI ≥30 and 149 with BMI <30. Prediction of miRNA targets and analysis of their expression were also performed to identify the potential epigenetic networks involved in obesity modulation. In the EC cohort, BMI ≥30 was significantly associated with 11 deregulated miRNAs. The topmost deregulated miRNAs were first analyzed in 84 EC samples by single miRNA assay and then tested in the TCGA dataset. This independent validation provided further confirmation about the significant difference of three miRNAs (miR‐199a‐5p, miR‐449a, miR‐449b‐5p) in normal‐weight EC patients versus EC patients with obesity, resulting significantly higher expressed in the latter. Moreover, the three miRNAs were significantly correlated with grade, histological type, and overall survival. Analysis of their target genes revealed that these miRNAs may regulate obesity‐related pathways. In conclusion, we identified specific miRNAs associated with BMI that are potentially involved in modulating obesity‐related pathways and that may provide novel implications for the clinical management of obese EC patients.
26 July 2025 in International Journal of Pharmaceutics
Ovarian cancer (OC) is the most lethal gynecologic malignancy, often diagnosed at advanced stages due to clinically silent peritoneal carcinomatosis. Although intraperitoneal (IP) chemotherapy enhances drug exposure, its effectiveness is hindered by rapid clearance, toxicity, and uneven distribution. To address these challenges, we developed a novel drug delivery system integrating paclitaxel (PTX)-loaded poly(lactic-co-glycolic acid) microparticles (PLGA-MPs) within calcium-alginate microbeads (Alg-MBs). This system aims to provide sustained drug release while minimizing adverse effects. PTX-loaded PLGA-MPs were prepared via solvent evaporation and encapsulated in Alg-MBs using a coaxial air jet generator. In vitro studies showed an initial burst release over five days, followed by sustained release until day 21, confirming the role of Alg-MBs in modulating drug diffusion. Cytotoxicity tests in 2D SKOV-3 OC cultures revealed dose-dependent effects, with increased PTX concentrations reducing cell viability. A 3D bioprinted tumor model was used to better replicate in vivo conditions and evaluate long-term efficacy. Sustained PTX release resulted in progressive tumor cell death over 21 days, with delayed but potent cytotoxicity at higher doses. These findings support hierarchical PTX microencapsulation for prolonged IP chemotherapy, while the 3D bioprinted model provided a more physiologically relevant platform for evaluating long-term therapeutic efficacy in OC treatment.